REDWOOD CITY, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly ...
Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...
Drug trafficker-turned-transport tycoon “Chepe Luna,” shot dead in Honduras last month, will be survived by his web of corruption, with an extensive network of collaborators in the Salvadoran state.
Hello, ladies and gentlemen. Thank you for standing by, and welcome to the Adverum's Webcast to discuss the 26-Week Interim Analysis of the ongoing LUNA Phase 2 trial that was presented earlier today ...
(RTTNews) - Adverum Biotechnologies (ADVM) reported results from the 26-week interim analysis of the LUNA Phase 2 trial of Ixo-vec in patients with wet age-related macular degeneration. Adverum said ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback